NBIX vs. BMY
Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY).
Performance
NBIX vs. BMY - Performance Comparison
Loading graphics...
NBIX vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | -6.54% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
BMY Bristol-Myers Squibb Company | 15.79% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
NBIX:
$13.59B
BMY:
$125.99B
NBIX:
$4.69
BMY:
$3.46
NBIX:
28.25
BMY:
17.84
NBIX:
0.56
BMY:
1.02
NBIX:
4.73
BMY:
2.61
NBIX:
4.18
BMY:
2.26
NBIX:
$2.86B
BMY:
$48.19B
NBIX:
$2.81B
BMY:
$30.43B
NBIX:
$719.10M
BMY:
$13.82B
Returns By Period
In the year-to-date period, NBIX achieves a -6.54% return, which is significantly lower than BMY's 15.79% return. Over the past 10 years, NBIX has outperformed BMY with an annualized return of 12.30%, while BMY has yielded a comparatively lower 2.90% annualized return.
NBIX
- 1D
- 0.62%
- 1M
- 0.14%
- YTD
- -6.54%
- 6M
- -3.24%
- 1Y
- 23.89%
- 3Y*
- 9.41%
- 5Y*
- 6.19%
- 10Y*
- 12.30%
BMY
- 1D
- 1.78%
- 1M
- -0.98%
- YTD
- 15.79%
- 6M
- 33.50%
- 1Y
- 8.90%
- 3Y*
- 0.70%
- 5Y*
- 3.49%
- 10Y*
- 2.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. BMY — Risk / Return Rank
NBIX
BMY
NBIX vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NBIX | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.71 | 0.31 | +0.40 |
Sortino ratioReturn per unit of downside risk | 1.13 | 0.64 | +0.49 |
Omega ratioGain probability vs. loss probability | 1.16 | 1.08 | +0.08 |
Calmar ratioReturn relative to maximum drawdown | 0.95 | 0.25 | +0.70 |
Martin ratioReturn relative to average drawdown | 2.31 | 0.39 | +1.92 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| NBIX | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.71 | 0.31 | +0.40 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.19 | 0.15 | +0.04 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.31 | 0.12 | +0.20 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.13 | 0.35 | -0.22 |
Correlation
The correlation between NBIX and BMY is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
NBIX vs. BMY - Dividend Comparison
NBIX has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.03%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.03% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
NBIX vs. BMY - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for NBIX and BMY.
Loading graphics...
Drawdown Indicators
| NBIX | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -72.03% | -25.18% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -25.79% | +4.89% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -47.67% | +4.78% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | -47.67% | +1.28% |
Current DrawdownCurrent decline from peak | -14.82% | -12.07% | -2.75% |
Average DrawdownAverage peak-to-trough decline | -44.05% | -22.40% | -21.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.59% | 16.06% | -7.47% |
Volatility
NBIX vs. BMY - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) and Bristol-Myers Squibb Company (BMY) have volatilities of 6.97% and 6.68%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| NBIX | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.97% | 6.68% | +0.29% |
Volatility (6M)Calculated over the trailing 6-month period | 23.03% | 19.39% | +3.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.89% | 28.61% | +5.28% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.22% | 23.68% | +8.54% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.43% | 25.08% | +14.35% |
Financials
NBIX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. BMY - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a gross profit of 787.90M and revenue of 805.50M. Therefore, the gross margin over that period was 97.8%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported an operating income of 210.90M and revenue of 805.50M, resulting in an operating margin of 26.2%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a net income of 153.70M and revenue of 805.50M, resulting in a net margin of 19.1%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.